Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,037.85% | -663.22% | -92.47% | -45.43% | 88.84% |
| Total Depreciation and Amortization | 761.97% | 1,500.00% | 376.67% | 39.86% | -131.70% |
| Total Amortization of Deferred Charges | -100.00% | -89.95% | -47.95% | 43.43% | 395.06% |
| Total Other Non-Cash Items | 334.14% | 6,750.00% | 154.36% | 115.50% | -12.11% |
| Change in Net Operating Assets | -93.39% | -88.72% | -1.99% | 69.37% | -36.71% |
| Cash from Operations | -128.91% | -59.36% | 22.84% | 83.02% | 140.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -85.19% |
| Other Investing Activities | -100.08% | -97.69% | -84.61% | 184.39% | 3,673.61% |
| Cash from Investing | 111.24% | 116.34% | 158.25% | 957.29% | 5,831.11% |
| Total Debt Issued | 0.00% | 0.00% | 13,233.33% | 13,233.33% | 6,566.67% |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | -5,900.00% | -2,900.00% |
| Issuance of Common Stock | -- | -- | 19.90% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -18.78% | 2,010.26% | 669.36% | 566.04% | 352.24% |
| Cash from Financing | 160.61% | 71.78% | 20.63% | -43.04% | -77.45% |
| Foreign Exchange rate Adjustments | -85.71% | 100.72% | 117.89% | -99.26% | -99.28% |
| Miscellaneous Cash Flow Adjustments | -- | -114.94% | -115.01% | -115.01% | -- |
| Net Change in Cash | -118.97% | 350.24% | 1,063.92% | 156.49% | 109.30% |
